Skip to main content

Table 1 Efficacy and side-effect of the rhGH treatment

From: EPHA4 haploinsufficiency is responsible for the short stature of a patient with 2q35-q36.2 deletion and Waardenburg syndrome

Course of GH treatment

HT (cm)

HT SDS (SDS)

Body weight (kg)

Bone age (y)

Drug dose (IU/kg)

IGF-1 (ng/ml)

Side-effect

prior treatment

83.5

−5.80

10.0

1.5

-

52.7

-

1 month of therapy

85.3

−5.47

10.0

-

0.11

75.8

N

3 month of therapy

87.0

−5.17

10.5

-

0.11

-

N

6 month of therapy

88.3

−5.09

11.0

2.0

0.10

99.1

N

7 month of therapy

89.5

−5.13

11.5

-

0.10

-

N

8 month of therapy

89.9

−5.24

10.5

-

0.11

-

N

11 month of therapy

92.2

−4.83

11.5

-

0.12

-

N

13 month of therapy

93.3

−4.76

11.0

2.0

0.12

128.0

N

15 months of therapy

94.8

−4.70

11.5

-

0.12

-

N

9 months out of therapy

98.1

−4.80

12.0

-

0.12

-

N